RIGVIR® Oncolytic Virotherapy. Advanced Cancer Treatment
Oncolytic virotherapy is an effective cancer treatment using special viruses, capable of finding and destroying malignant tumor cells in the body. Rigvir is the first registered and still the one and only genetically unmodified virus available worldwide.
After being administered, the virus finds and infects malignant tumor cells in a process called oncotropism. The virus replicates itself in the cells of a malignant tumor destroying them in a process called oncolysis. Viruses not only destroy cancer cells but also activate the body’s natural immune system, which also targets malignant cells.
The goal of virotherapy, not unlike that of radiation therapy and chemotherapy, is to destroy cancer cells.
Virotherapy is recognized as a safe and efficient cancer treatment method.
Oncolytic virotherapy is an official, innovative, and effective cancer treatment using a special virus, which is capable of finding and destroying cells of a malignant tumor in the human body. The medicinal product is intramuscularly injected into a body.
Virotherapy takes place on an in-patient or out-patient basis, depending on the situation and the patient’s health condition. The treatment takes place pursuant to a tailor-made treatment protocol and in accordance with the application guidelines under the supervision of the doctor. The average treatment period is 3 years during which regular monitoring of analyses and a patient observation takes place.
Cancer virotherapy is a treatment method that is gentle to the body and has minimum side effects. The most common side effect is slightly increased body temperature (up to 37.5°C, 99.5°F) lasting one to three days.
Rigvir® For Cancer Treatment Is A Virus Affecting Only Malignant Cells And Causing No Side Effects
Studies circulating around Rigvir® (short for “Riga virus”) started in the mid-1950s in Latvia by a microbiologist professor Aina Muceniece. The scientist was the first to discover a cancer-killing feature of the drug with little or no side effects.
Patients from roughly 25 countries around the world have started using Rigvir® to treat:
Melanoma, Lung cancer, Various types of sarcoma, Neuroendocrine tumors, Glioblastoma, Ovarian cancer, Uterine cancer, Breast cancer, Bladder cancer, Prostate cancer, Kidney cancer, Pancreatic cancer, Colorectal cancer
Rigvir® affects only cancer cells and destroys them from within leaving normal cells untouched. It is stored in vials for future injection. The explanation may be hard to perceive, that’s why we also have a 5-minute video for you to see how Rigvir® works.
What Clinical Trials Say About Rigvir®: Prolonging Life To Melanoma, Lung Cancer, And Sarcoma Patients
A medical journal APMIS (Acta Pathologica, Microbiologica et Immunologica Scandinavica) published in July 2016 the results of clinical trials conducted for patients diagnosed with stage IV melanoma with metastases, stage IIIA small cell lung cancer, and stage 4 histiocytic sarcoma. They look as follows:
“All patients started Rigvir® treatment within a few months after being diagnosed and are currently continuing Rigvir® treatment… Using current standard treatments, the survival of patients with the present diagnoses is low. In contrast, the patients described here were diagnosed 3.5, 7.0, and 6.6 years ago, and their condition has improved and been stable for over 1.5, 6.5, and 4 years, respectively. These observations suggest that virotherapy using Rigvir® can successfully be used in the long-term treatment of patients with melanoma stage IV M1c, small cell lung cancer stage IIIA, and histiocytic sarcoma stage IV…”
The Oncolytic Virus in Cancer Diagnosis and Treatment
Please get in touch with us to be qualified for RIGVIR® therapy by certified doctors:
The following items shall be submitted to us for the assessment (email@example.com):
Full Blood Count, Ultrasound research results, CT scans, MRIs, PT, Biopsy research results
Oncolytic Virotherapy (OV) is quickly moving toward the forefront of modern medicines
Oncolytic Virotherapy (OV) type of oncology treatment is quickly moving toward the forefront of modern medicines.
The reward for the decades of research invested into developing oncolytic viruses that selectively replicate in and lyse tumor cells while sparking anticancer adaptive immunity is presenting in the form of durable therapeutic responses.
How Oncolytic Viruses Destroy Cancer Cells – What is an Oncolytic Virus?
Oncolytic viral therapy is a relatively modern approach to treating certain types of cancers. An Oncolytic virus is a ‘biological weapon’ that acts against cancer cells. It has the ability to infect the cancerous tumor and lyse (kill) the cancer cells while preserving normal cells. Oncolytic virus therapies are proving to be a viable modality for use in cancer treatments both alone and used in combination with other treatment options. The medical community is overly excited about oncolytic viral therapy as it is showing efficacy in many hard-to-treat cancerous tumors such as melanoma.
The Principle Mechanism of Oncolytic Viruses
The principal action of Oncolytic viruses is based upon the characteristics of the select virus being used for treatment. Rather exciting at the forefront of effective cancer treatments, oncolytic viruses are being harnessed for their natural ability to attack cancer cells. Additionally, there are cancers that are known to be especially vulnerable to specific viruses that allow for direct targeting of the tumor. They work in two distinct, but highly effective ways.
The first mechanism of efficacy is that the select virus preferentially replicates itself inside the cancer cell resulting in the destruction of the cancerous cell but does not harm healthy cells. It does this naturally. The select modified virus is attracted to especially hard tumors under the skin and it gets inside the tumor and spreads. This action halts the spread of cancer and also kills the affected cells.
The second mechanism is that the virus assists the immune function of the body itself by activating antibodies within the body and results in the lysing of cancer cells. It accomplishes this by triggering the production of T-cells, which are a type of white blood cell that plays a central role in the body’s immune function.
What Cancers Are Being Treated with Oncolytic Viruses?
Many cancers are being treated by the use of oncolytic therapy. Revolutionary progress is being gained every day by clinical studies of viruses with regard to otherwise irresponsive cancer tumors. There are several viruses used in oncolytic viral therapy – narrowly designed to target many types of solid cancerous tumors.
Oncolytic viral therapy appeals to cancer patients because they don’t experience hair loss and related maladies. Oncolytic viruses are well tolerated and the side effects are minimal and tend to disappear within a few days.
Why do patients choose Oncolytic Virotherapy?
Virotherapy destroys tumor cells selectively without affecting the healthy cells of the body, this therapy has no side effects
Oncolytic Virotherapy stimulates the body’s natural defense mechanisms by activating the immune system, which is often suppressed by other treatment methods, it is a safe therapy, with promising results in various types of cancer.
Oncolytic Virotherapy can be used against tumors that don’t respond well to radiation or chemotherapy, such as melanoma.
Virotherapy can be used at various stages throughout the treatment process: before or after surgery and between radiation or chemotherapy treatments and in combination with other integrative cancer treatment methods.
How Oncolytic Viruses Differ from Other Therapies?
Unlike traditional therapies, oncolytic viruses are designed to specifically target cancer cells while leaving healthy cells intact. As an appealing benefit to patients, oncolytic viral therapy works without the harsh side effects as conventional therapies such as chemotherapy. Most of the post-therapy symptoms are reported to dissipate within a few days. Also, oncolytic viruses show the ability to kill cancer cells that have become resistant to other treatment methods. Many oncolytic viruses are systemically administered and have a greater safety quotient than other related therapies.
Common Side Effects of Oncolytic Viral Therapy.
Oncolytic viral therapies are well-tolerated, making them a viable treatment option against a variety of cancer types. Some of the more common side-effects reported are “flu-like” symptoms. They include symptoms such as chills, fever, nausea, loss of appetite, and muscle ache. Some reported pain at the injection sites, but mostly a low incidence of serious adverse reactions while being treated is reported.